Edesa Biotech is trading at $5.33 (+5.54%), with the move appearing primarily sector-driven amid stronger biotech sentiment following argenx’s $2.2 billion acquisition of Forte Biosciences.
- The transaction includes argenx’s $77-per-share tender offer.
- Edesa Biotech has no identified company-specific announcement dated August 7, 2026; its official news page lists releases only through June 11.
- Edesa Biotech is participating in the broader biotech rally rather than responding to a newly disclosed corporate catalyst.